Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice.

Diepenbroek M, Casadei N, Esmer H, Saido TC, Takano J, Kahle PJ, Nixon RA, Rao MV, Melki R, Pieri L, Helling S, Marcus K, Krueger R, Masliah E, Riess O, Nuber S.

Hum Mol Genet. 2014 Aug 1;23(15):3975-89. doi: 10.1093/hmg/ddu112. Epub 2014 Mar 11.

2.

Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice.

Schell H, Hasegawa T, Neumann M, Kahle PJ.

Neuroscience. 2009 Jun 2;160(4):796-804. doi: 10.1016/j.neuroscience.2009.03.002. Epub 2009 Mar 9.

PMID:
19272424
3.

Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain.

Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Schindzielorz A, Okochi M, Leimer U, van Der Putten H, Probst A, Kremmer E, Kretzschmar HA, Haass C.

J Neurosci. 2000 Sep 1;20(17):6365-73.

4.

Overexpression of synphilin-1 promotes clearance of soluble and misfolded alpha-synuclein without restoring the motor phenotype in aged A30P transgenic mice.

Casadei N, Pöhler AM, Tomás-Zapico C, Torres-Peraza J, Schwedhelm I, Witz A, Zamolo I, De Heer R, Spruijt B, Noldus LP, Klucken J, Lucas JJ, Kahle PJ, Krüger R, Riess O, Nuber S.

Hum Mol Genet. 2014 Feb 1;23(3):767-81. doi: 10.1093/hmg/ddt467. Epub 2013 Sep 24.

5.

Impaired c-Fos and polo-like kinase 2 induction in the limbic system of fear-conditioned α-synuclein transgenic mice.

Schell H, Boden C, Chagas AM, Kahle PJ.

PLoS One. 2012;7(11):e50245. doi: 10.1371/journal.pone.0050245. Epub 2012 Nov 27.

6.

Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease.

Zhou W, Milder JB, Freed CR.

J Biol Chem. 2008 Apr 11;283(15):9863-70. doi: 10.1074/jbc.M710232200. Epub 2008 Jan 30.

7.

Accumulation of α-synuclein triggered by presynaptic dysfunction.

Nakata Y, Yasuda T, Fukaya M, Yamamori S, Itakura M, Nihira T, Hayakawa H, Kawanami A, Kataoka M, Nagai M, Sakagami H, Takahashi M, Mizuno Y, Mochizuki H.

J Neurosci. 2012 Nov 28;32(48):17186-96. doi: 10.1523/JNEUROSCI.2220-12.2012.

8.

Motor impairment and aberrant production of neurochemicals in human alpha-synuclein A30P+A53T transgenic mice with alpha-synuclein pathology.

Ikeda M, Kawarabayashi T, Harigaya Y, Sasaki A, Yamada S, Matsubara E, Murakami T, Tanaka Y, Kurata T, Wuhua X, Ueda K, Kuribara H, Ikarashi Y, Nakazato Y, Okamoto K, Abe K, Shoji M.

Brain Res. 2009 Jan 23;1250:232-41. doi: 10.1016/j.brainres.2008.10.011. Epub 2008 Nov 1.

PMID:
18992718
9.

Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology.

Ulusoy A, Febbraro F, Jensen PH, Kirik D, Romero-Ramos M.

Eur J Neurosci. 2010 Aug;32(3):409-22. doi: 10.1111/j.1460-9568.2010.07284.x.

PMID:
20704592
10.

Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation.

Dufty BM, Warner LR, Hou ST, Jiang SX, Gomez-Isla T, Leenhouts KM, Oxford JT, Feany MB, Masliah E, Rohn TT.

Am J Pathol. 2007 May;170(5):1725-38.

11.

Calpastatin overexpression limits calpain-mediated proteolysis and behavioral deficits following traumatic brain injury.

Schoch KM, Evans HN, Brelsfoard JM, Madathil SK, Takano J, Saido TC, Saatman KE.

Exp Neurol. 2012 Aug;236(2):371-82. doi: 10.1016/j.expneurol.2012.04.022. Epub 2012 May 1.

12.

Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?

Schulz-Schaeffer WJ.

Biomolecules. 2015 Jul 16;5(3):1467-79. doi: 10.3390/biom5031467. Review.

13.

A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease.

Liu CW, Giasson BI, Lewis KA, Lee VM, Demartino GN, Thomas PJ.

J Biol Chem. 2005 Jun 17;280(24):22670-8. Epub 2005 Apr 19.

14.

The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease.

Yasuda T, Mochizuki H.

Apoptosis. 2010 Nov;15(11):1312-21. doi: 10.1007/s10495-010-0486-8. Review.

PMID:
20221696
15.

Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation.

Lázaro DF, Rodrigues EF, Langohr R, Shahpasandzadeh H, Ribeiro T, Guerreiro P, Gerhardt E, Kröhnert K, Klucken J, Pereira MD, Popova B, Kruse N, Mollenhauer B, Rizzoli SO, Braus GH, Danzer KM, Outeiro TF.

PLoS Genet. 2014 Nov 13;10(11):e1004741. doi: 10.1371/journal.pgen.1004741. eCollection 2014 Nov.

16.

Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease.

Simões AT, Gonçalves N, Koeppen A, Déglon N, Kügler S, Duarte CB, Pereira de Almeida L.

Brain. 2012 Aug;135(Pt 8):2428-39. doi: 10.1093/brain/aws177.

17.

Targeting alpha-synuclein for the treatment of Parkinson's disease.

Rohn TT.

CNS Neurol Disord Drug Targets. 2012 Mar;11(2):174-9. Review.

PMID:
22483285
18.

Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo.

Rockenstein E, Nuber S, Overk CR, Ubhi K, Mante M, Patrick C, Adame A, Trejo-Morales M, Gerez J, Picotti P, Jensen PH, Campioni S, Riek R, Winkler J, Gage FH, Winner B, Masliah E.

Brain. 2014 May;137(Pt 5):1496-513. doi: 10.1093/brain/awu057. Epub 2014 Mar 24.

19.
20.

Biochemical and morphological consequences of human α-synuclein expression in a mouse α-synuclein null background.

Prasad K, Tarasewicz E, Strickland PA, O'Neill M, Mitchell SN, Merchant K, Tep S, Hilton K, Datwani A, Buttini M, Mueller-Steiner S, Richfield EK.

Eur J Neurosci. 2011 Feb;33(4):642-56. doi: 10.1111/j.1460-9568.2010.07558.x. Epub 2011 Jan 28.

Items per page

Supplemental Content

Write to the Help Desk